Results with PCSK9 inhibitor in ODYSSEY OUTCOMES above expectations, mortality benefit included - PACE-CME

Results with PCSK inhibitor in ODYSSEY OUTCOMES above expectations mortality benefit included

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

What do we know now that could have changed the history of CETP inhibition?: genetics and biology
What do we know now that could have changed the history of CETP inhibition?: genetics and biology
MinuteCE®
What do we know now that could have changed the history of CETP inhibition?: genetics and biology
0.50 program credits
- John Kastelein, MD, PhD
0.50 program credits
MinuteCE®
Clinical scenarios addressing residual risk in ASCVD: Understanding the role of triglycerides and EPA
0.50 credits 3 episodes
- Prof. Alberto Zambon MD, PhD, FAHA
- Prof. Kausik Ray, MBChB, MD, MPhil
- Azfar Zaman, MD
0.50 credits 3 episodes
CETP inhibition: Lessons from two decades of clinical trials
CETP inhibition: Lessons from two decades of clinical trials
MinuteCE®
CETP inhibition: Lessons from two decades of clinical trials
0.50 program credits
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
0.50 program credits
MinuteCE®
Innovating the clinical management of LDL-c: Exploring CETP as therapeutic target
0.50 credits 3 episodes
- John Kastelein, MD, PhD
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
- Erin D. Michos, MD, MHS, FACC, FAHA, FASE
0.50 credits 3 episodes